|
|
|
|
The production of viral vectors for the manufacturing of gene therapies and vaccines depends on the development and utilization of high-quality master virus seed stocks (MVSS) and working virus seed stocks (WVSS). Gain insight into two cases where clients were enabled to overcome obstacles during virus bank manufacturing.
|
|
|
|
|
Viral clearance studies for non-enveloped viral vectors have been performed less frequently than those of enveloped viral vectors. For this reason, the virus inactivation steps and the model virus panel for clearance studies may not be as clear. Gain a better understanding of viral clearance studies for AAV vectors.
|
|
|
|
|
Next Generation Sequencing (NGS) is transforming gene therapy development by enabling deeper insight into viral vector quality, integrity, and safety. See how advanced sequencing approaches support more consistent manufacturing and stronger regulatory readiness, and accelerated progress toward clinical success.
|
|
|
|
|
Here, we outline the processes and best practices applied at a GMP facility to optimize the production of working virus seed stocks and master virus seed stocks. Learn about the relevant regulatory and testing requirements as well as key factors for ensuring the successful manufacture of virus banks.
|
|
|
|
|
|
|
A virus bank is a vital part of manufacturing. Choosing a partner with expertise ensures high-quality banks are used in the development of your therapy. At our cGMP facility, we excel at producing master virus seed stocks (MVSS), as well as subsequent production of working virus seed stocks (WVSS). Connect with our experts to discuss your upcoming project today.
|
|
|
